The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 1, 2010, Pages 100-108

  Picard, N ^a,b,c   Yee, S W ^d   Woillard, J B ^a,c   Lebranchu, Y ^e   Le Meur, Y ^a,f   Giacomini, K M ^d   Marquet, P ^a,b,c  

^a Univ Limoges   (France)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF LIMOGES   (France)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY HOSPITAL OF TOURS   (France)

^f BREST UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID PHENYLGLUCURONIDE; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 1A2; ORGANIC ANION TRANSPORTER 1B1; ORGANIC ANION TRANSPORTER 1B3; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEK293; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG UPTAKE; ENTEROHEPATIC CIRCULATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN CELL; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM;

CELL LINE; GENETIC VARIATION; HUMANS; MYCOPHENOLIC ACID; ORGANIC ANION TRANSPORTERS; PEPTIDES; POLYMORPHISM, GENETIC;

EID: 72849122949     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.205     Document Type: Article

References (29)

1. Bullingham, R.E., Nicholls, A.J. & Kamm, B.R. Clinical pharmacokinetics of mycophenolate mofetil. Clin. Pharmacokinet. 34, 429-455 (1998).
2. Hesselink, D.A. et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am. J. Transplant. 5, 987-994 (2005).
3. Picard, N., Prémaud, A., Rousseau, A., Le Meur, Y. & Marquet, P. a comparison of the efect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. Br. J. Clin. Pharmacol. 62, 477-484 (2006).
4. Smak Gregoor, P.J., Van Gelder, T., Hesse, C.J., Van der Mast, B.J., Van Besouw, N.M. & Weimar, W. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol. Dial. Transplant. 14, 706-708 (1999).
5. Miura, M. et al. Infuence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in japanese renal transplant recipients. Ther. Drug Monit. (2008); e-pub ahead of print 7 august 2008.
6. Miura, M. et al. Infuence of SLCO1B1, 1B3, 2B1 and aBCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in japanese renal transplant recipients. Eur. J. Clin. Pharmacol. 63, 1161-1169 (2007). (Pubitemid 350112768)
7. Hamada, A. et al. Efect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin. Cancer Res. 14, 3312-3318 (2008).
8. Naesens, M., Kuypers, D.R., Verbeke, K. & Vanrenterghem, Y. Multidrug resistance protein 2 genetic polymorphisms infuence mycophenolic acid exposure in renal allograft recipients. Transplantation 82, 1074-1084 (2006).
9. Baldelli, S. et al. C-440T/T-331C polymorphisms in the UGT1a9 gene afect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics 8, 1127-1141 (2007).
10. Niemi, M. Role of OaTP transporters in the disposition of drugs. Pharmacogenomics 8, 787-802 (2007).
11. Franke, R.M., Scherkenbach, L.A. & Sparreboom, A. Pharmacogenetics of the organic anion transporting polypeptide 1a2. Pharmacogenomics 10, 339-344 (2009).
12. Letschert, K., Keppler, D. & König, J. Mutations in the SLCO1B3 gene afecting the substrate specifcity of the hepatocellular uptake transporter OaTP1B3 (OaTP8). Pharmacogenetics 14, 441-452 (2004).
13. Treiber, A., Schneiter, R., Häusler, S. & Stieger, B. Bosentan is a substrate of human OaTP1B1 and OaTP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin a, rifampicin, and sildenafl. Drug Metab. Dispos. 35, 1400-1407 (2007).
14. Shitara, Y., Itoh, T., Sato, H., Li, A.P. & Sugiyama, Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin a. J. Pharmacol. Exp. Ther. 304, 610-616 (2003).
15. Simonson, S.G. et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin. Pharmacol. Ther. 76, 167-177 (2004).
16. Bernard, O. & Guillemette, C. The main role of UGT1a9 in the hepatic metabolism of mycophenolic acid and the efects of naturally occurring variants. Drug Metab. Dispos. 32, 775-778 (2004).
17. Girard, H. et al. Identifcation of common polymorphisms in the promoter of the UGT1a9 gene: evidence that UGT1a9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 14, 501-515 (2004).
18. Kuypers, D.R., Naesens, M., Vermeire, S. & Vanrenterghem, Y. The impact of uridine diphosphate-glucuronosyltransferase 1a9 (UGT1a9) gene promoter region single-nucleotide polymorphisms T-275a and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin. Pharmacol. Ther. 78, 351-361 (2005).
19. Johnson, L.A., Oetting, W.S., Basu, S., Prausa, S., Matas, A. & jacobson, P.A. Pharmacogenetic efect of the UGT polymorphisms on mycophenolate is modifed by calcineurin inhibitors. Eur. J. Clin. Pharmacol. 64, 1047-1056 (2008).
20. Van Schaik, R.H. et al. UGT1a9-275Ta/-2152C T polymorphisms correlate with low MPa exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin. Pharmacol. Ther. 86, 319-327 (2009).
21. Prémaud, A. et al. Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at diferent postgrafting periods. Ther. Drug Monit. 27, 354-361 (2005).
22. van Hest, R.M., Mathot, R.A., Pescovitz, M.D., Gordon, R., Mamelok, R.D. & van Gelder, T. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J. Am. Soc. Nephrol. 17, 871-880 (2006).
23. Cattaneo, D., Perico, N., Gaspari, F., Gotti, E. & Remuzzi, G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 62, 1060-1067 (2002).
24. Prémaud, A., Rousseau, A., Le Meur, Y., Lachâtre, G. & Marquet, P. Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPa in renal transplant recipients and consequences for therapeutic drug monitoring. Ther. Drug Monit. 26, 609-619 (2004).
25. Le Meur, Y. et al. Individualized mycophenolate mofetil dosing based on drug exposure signifcantly improves patient outcomes after renal transplantation. Am. J. Transplant. 7, 2496-2503 (2007).
26. Prémaud, A. et al. a double absorption-phase model adequately describes mycophenolic acid plasma profles in de novo renal transplant recipients given oral mycophenolate mofetil. Clin. Pharmacokinet. 44, 837-847 (2005).
27. Le Meur, Y. et al. CyP3a5&z.ast;3 infuences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin. Pharmacol. Ther. 80, 51-60 (2006).
28. Tregouet, D.A. & Tiret, L. Cox proportional hazards survival regression in haplotype-based association analysis using the Stochastic-EM algorithm. Eur. J. Hum. Genet. 12, 971-974 (2004).
29. Stephens, M. & Donnelly, P. a comparison of bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 73, 1162-1169 (2003).